Mednax Inc (MD)
Return on equity (ROE)
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Net income | US$ in thousands | -60,408 | 66,335 | 130,964 | -796,488 | -1,497,700 |
| Total stockholders’ equity | US$ in thousands | 849,061 | 891,632 | 896,487 | 747,485 | 1,499,000 |
| ROE | -7.11% | 7.44% | 14.61% | -106.56% | -99.91% |
December 31, 2023 calculation
ROE = Net income ÷ Total stockholders’ equity
= $-60,408K ÷ $849,061K
= -7.11%
From the data provided, we can observe significant fluctuations in Pediatrix Medical Group Inc's Return on Equity (ROE) over the past five years. In 2023, the company experienced a negative ROE of -7.11%, indicating that it generated a net loss relative to its shareholders' equity. This contrasts with the positive ROE values in 2022 (7.44%) and 2021 (14.61%), suggesting a relatively healthy return on equity during those years.
However, the ROE plummeted drastically in 2020 and 2019, reaching -106.56% and -99.91% respectively. These negative ROE figures signify that the company's earnings were not sufficient to cover the shareholders' equity, resulting in a loss-making situation and potential concerns regarding financial stability and profitability.
Overall, the inconsistent performance of Pediatrix Medical Group Inc's ROE raises questions about its operational efficiency, profitability, and utilization of equity capital over the analyzed period. Further analysis and investigation into the underlying causes of these fluctuations would be necessary to make informed assessments about the company's financial health and prospects.
Peer comparison
Dec 31, 2023